CD200 is induced by ERK and is a potential therapeutic target in melanoma
J. Clin. Invest. Kimberly B. Petermann, et al. 117:3922 doi:10.1172/JCI32163 [Go to this article.]

Figure 1
CD200 is a p-ERK target in melanoma. (A) Dendrogram of melanoma-specific transcripts that are regulated by p-ERK expression in indicated melanoma cell lines. Melanoma cell lines with high levels of activated ERK (black) show increased CD200 expression. Melanoma cell lines with low ERK activity lacking RAS/RAF mutation (blue) or treated with UO126 (a MEK inhibitor; green) and normal human melanocytes (red) have low expression of CD200 and other known ERK targets. (B) TaqMan qRT-PCR of CD200 expression after U0126 treatment of human melanoma cell lines. WM2664 and SKMEL24 cell lines were treated with U0126 for 4, 8, and 24 hours. CD200 expression was normalized to a control transcript (18S). Error bars are ± SEM. *P < 0.05. (C) Immunoblot showing ERK activation in melanoma cell lines. Protein lysates from the indicated melanoma cell lines were immunoblotted with anti–p-ERK and anti–total ERK. (D) Flow cytometry was performed on melanoma cell lines WM2664, SKMEL24, and SKMEL28 (high p-ERK) and melanoma cell lines PMWK, Mel505, and SKMEL187 (low p-ERK). The high p-ERK lines express high levels of CD200, while low p-ERK lines express low levels of CD200.